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A promising option in substance abuse treatment is the Community Reinforcement Ap-
proach (CRA). The opioid antagonist naltrexone (NTX) may work in combination with
nicotine replacement therapy (NRT) to block the effects of smoking stimuli in abstinent
smokers. Effects of lower doses than 50 mg/dd. have not been reported. A study was
conducted in Amsterdam in 2000/2001 with the objective to explore the effects of the
combination NTX (25/50-mg dd.), NRT, and CRA in terms of craving and abstinence.
In a randomized open label, 2 × 2 between subjects design, 25 recovered spontaneous
pneumothorax (SP) participants received 8 weeks of treatment. Due to side effects, only
3 participants were compliant in the 50-mg NTX condition. Craving significantly de-
clined between each measurement and there was a significant interaction between de-
cline in craving and craving measured at baseline. The abstinence rate in the CRA group
was nearly double that in the non-psychosocial therapy group (46% vs. 25%; NS) at
3 months follow-up after treatment.
Keywords naltrexone; nicotine replacement therapy (NRT); community reinforce-
ment approach (CRA); smoking; craving; spontaneous pneumothorax (SP)
Introduction
Naltrexone (NTX), which is traditionally used to prevent alcohol and opioid abuse, recently
emerged in the tobacco literature (Krishnan-Sarin et al., 2003). It is suggested that there may
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be a link between opiates and nicotine (Krishnan-Sarin et al., 1999). Under controlled labo-
ratory conditions, where habitual smokers smoked cigarettes, an increase in beta-endorphin
levels co-occurred with increases in plasma nicotine concentrations (Pomerleau et al., 1983).
It is conceivable that nicotine stimulates endogenous opioid release, which provides positive
reinforcement for smoking. Subsequently, an opioid antagonist, such as NTX, may (par-
tially) block these rewarding effects. In a study by Sutherland et al. (1995), it was suggested
that NTX reduced the perceived difficulty of abstaining during 24-hr cigarette withdrawal.
Some additional support for the use of NTX came from a study by King and Meyer (2000),
who demonstrated that NTX in controlled conditions significantly reduced the total number
of cigarettes smoked.
In a study conducted by Wewers et al. (1998) it was demonstrated that plasma nicotine
levels, number of cigarettes smoked daily, and self-reported satisfaction with smoking were
significantly lower among those treated with NTX. A review by David et al. (2002), however,
showed that short-term trials of NTX yielded conflicting results with regard to effects
on ad libitum smoking, withdrawal symptoms, mood states, subjective and physiological
responses to smoking. In addition, several placebo-controlled studies ascertained no support
for NTX on a variety of biochemical and behavioral measures of nicotine intake or even
produced negative effects on mood (Brauer et al., 1999; Wong et al., 1999; Sutherland
et al., 1995). Thus, at best, it remains unclear whether NTX helps smokers quit (David
et al., 2002). However, to our knowledge, all NTX studies on smoking cessation examined
the effects of the 50-mg daily dose. Only one study could be identified as using 100 mg dd.
of NTX (Sutherland et al., 1995). This study demonstrated no dose response effect between
50 and 100 mg NTX per day and no other studies could be identified with lower dosages.
In a review, Silagy et al. (2002) concluded that all forms of Nicotine Replacement
Therapy (NRT) are effective as part of a strategy to promote smoking cessation. Conse-
quently, it has been demonstrated that the concurrent use of NTX and NRT is beneficial
for smoking cessation (Hutchison et al., 1999; Krishnan-Sarin et al., 2003), because it
may ameliorate withdrawal symptoms, dysphoria, and sedation (Hutchison et al., 1999).
Additionally, it is suggested that NTX augments the efficacy of NRT in terms of craving
(Hutchison et al., 1999; Krishnan-Sarin et al., 2003). Also, the single use of NTX may
reduce craving (Houtsmuller et al., 1997; King and Meyer, 2000). Craving is thought to
play an important role in maintaining regular smoking patterns in smokers and in leading
to relapse in smokers attempting to quit (Houtsmuller and Stitzer, 1999). Although still not
understood completely, craving is mainly referred to as a compulsory desire to use (c.f.
Robinson and Berridge, 1993, 2001). In addition, craving is considered to be a complex,
dynamic, multidimensional phenomenon (Baraba´si, 2003; Buscema, 1998), consisting of
biological, psychological, and social components.
With respect to psychosocial treatments, the Community Reinforcement Approach
(CRA) is a promising option, with evidence in favor of using CRA in alcohol, cocaine, and
opioid treatment (Roozen et al., 2004). CRA has also been mentioned in relation to smoking
cessation (Poldrugo et al., 2002). CRA is a comprehensive cognitive behavioral oriented
treatment package that focuses on environment (community)-organism interactions to re-
arrange a substance abusing lifestyle (Meyers and Smith, 1995). It is based on the view
that substance-related reinforcers and the relative lack of alternative reinforcers unrelated
to substance abuse maintain dependence. Development of alternative rewarding activities
that are incompatible with substance use is essential to initiate and maintain abstinence
(Schottenfeld, et al., 2000). CRA integrates concomitant administration of pharmacolog-
ical agents with psychosocial aspects. It seems likely that CRA, as a novel multi-faceted
approach, is appropriate to foster abstinence in smoking cessation therapy. In the present
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study this expectation was addressed. The objective of this study was to explore 1) the
effects of CRA in terms of abstinence, therapy retention, and treatment satisfaction, and
2) a dose response effect of NTX in terms of craving and abstinence.
Method
Participants
Twenty-five participants were recruited from a database of 181 recovered spontaneous pneu-
mothorax (SP) patients treated at the VU medical center (22 participants) and Slotervaart
hospital (3 participants) in Amsterdam, the Netherlands. SP is considered to be a smoking
related disease, because tobacco use enhances the chance of having peripheral airway in-
flammation (Snider, 1992), which has a role in the pathogenesis of idiopathic SP (Schramel
et al., 1997; Smit, 1999). The chances of contracting SP is 8-22 fold higher when peo-
ple smoke (Bense et al., 1987) and smoking cessation reduces this chance (Sadikot et al.,
1997). All participants were contacted by telephone to enquire if they wanted to participate.
Participants were included if they were between the ages of 18 and 65, smoked at least 15
cigarettes daily for a minimum of 5 years, and expressed the wish to stop smoking. Partici-
pants should have performed at least three unsuccessful attempts to stop smoking in the past
5 years. They should not simultaneously participate in another smoking cessation treatment
and they should have the collaboration of a non-smoking concerned significant other to
assist the participant in his attempt to stop smoking. Participants were excluded if they were
dependent on opioids, cannabis, or alcohol. All participants gave written informed consent.
Procedure
The treatment (T1-T9) was provided for 8 weeks (Fig. 1). Prior to the treatment, participants
and their significant other (i.e., supportive partner or friend) were invited for an information
visit (T0) to collect socio-demographic, medical history data (Table 1), and to explain
the rationale and procedure. Participants were consecutively randomized by using a block
design and were allocated to four treatment groups (Fig. 1). In the week following the
first treatment visit (T1) the administration of NTX (Antaxone©R), which was administered
in oral solution, was gradually increased from 5 mg to 25 mg. NRT (Nicotinell©R) was
tapered from 21 mg/24 hr to 7 mg/ 24 hr (see Fig. 1). The rationale for this non-standard
use of the NRT taper procedure was to ameliorate possible withdrawal symptoms and
to reduce possible side effects of the NTX induction. At T2 the NTX dosages were in
alignment with the randomization procedure: 25 mg NTX, 25 mg NTX + CRA therapy,
50 mg NTX, and 50 mg NTX + CRA therapy. The timing of the clinical and laboratory
assessments is summarized in Table 2. At the weekly visits, data was collected and the NTX
was administered (HJW/SvB). The participants allocated to the CRA condition received
concomitant CRA treatment at visits 1, 2, 3, 5, and 7. The non-treatment group received
no additional treatment. Each participant was seen at the same time of day at all visits.
A follow-up took place 3 months after the treatment visits, and a second follow-up was
conducted 11/2 years later by telephone to assess continuous abstinence. Only participants
who had been abstinent at 3 months were contacted for a second follow-up. Drop-outs were
considered as smokers.
CRA. The cognitive behavioral treatment was based on CRA (Meyers and Smith, 1995)
to give support during smoking cessation, and was protocol driven (Roozen and Kerkhof,
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Figure 1. Treatment plan and flowchart of the visits (T0 to T10). T10 and T11 are follow-up contacts.
T11 was only a telephone contact. I = Intake, S = Selection, R = Randomization, and F = Follow-up.
The detoxification encompassed a gradual increase of NTX from 5 mg (day 1 & 2), 10 mg (day 3
& 4), 15 mg (day 5), 20 mg (day 6) to 25 mg (day 7). The NRT administration was tapered down
by applying 21 mg/24 hr (day 1 & 2), 14 mg/24 hr (day 2–5) and 7 mg/ 24 hr (day 6 & 7). For
particpants allocated to both 50 mg NTX conditions, NTX was further increased from 25 mg to 50 mg
at T2.
2000). Masters-level psychology students conducted this therapy, which took five sessions.
Treatment integrity was guided by a 3-day training course and weekly individual supervision
(HGR). Sessions focused on motivation, adherence to treatment and NTX administration,
skill training, functional analysis, and creating a monitoring system. The “Stimulus Control”
procedure (Azrin et al., 1994) was employed to eliminate high-risk social situations that
are precursors to smoking and to increase the amount of time spent engaging in smoking-
incompatible activities.
Objective and Subjective Measures. An overview of the measures used is provided in
Table 3. The success of cessation is measured by abstinence according to self-report. Of the
collected urine samples, the cotinine values were analyzed to verify self-reported smoking
status.
Design and Statistical Analysis
A 2 × 2 factorial between-subjects design was utilized. The significance level was set
at p < 0.05. Descriptive statistics, paired sample T-test, Spearman’s rho, and one-way
ANOVA’s were used to compare sample characteristics. Logit analyses were conducted
to analyze main effects or significant interactions between the four conditions. A Gen-
eral Linear Model (GLM) repeated measures analysis was conducted, with as between-
subjects factors the NTX doses (25 mg vs. 50 mg) and CRA therapy (therapy vs. none),
and as the within-subjects factor the 10 VAS measurements. The baseline VAS was used as
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Table 2
Flow chart of study assessments points
Clinical measures/
Intervention T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11
Time (hour)∗ 1.5 1.0 0.5 0.25 0.5 0.25 0.25 0.25 0.25 1.5 0.5 0.1
Soc. Demographic
data

VAS health status 
Physical
examination

Urine sample     
Self-report smoking      
VAS (craving)           
VAS (taste)           
VAS (CRA) 
CSQ-8 
SCL-90  
CRA∗∗     
Notes: ∗Average time needed to assess data, administer medication, provide instruction, informa-
tion, and advice, document side effects, etc.
∗∗Only for participants allocated to the CRA condition. Each CRA treatment session lasted about
60 minutes.
covariate. Missing data analysis, considering the VAS, were conducted by the expectation
maximization (EM)-algorithm. After this, a T-test was used to analyze if the craving reduced
linearly or remained constant. The tests of the within subjects effects were analyzed using
the univariate approach with Huynh-Feldt correction.
Results
General Outcomes
Sociodemographic characteristics, scores on the SCL-90, and alcohol use were not statis-
tically different between the four groups at baseline (Table 1). The scores on the SCL-
90 at baseline and at the end of treatment did not differ significantly, except for a de-
crease in depression (p = 0.026, Cohen’s d = 0.35; Table 4). One week of nicotine
replacement was sufficient to ameliorate withdrawal symptoms, but participants preferred
a longer use of NRT. Eight participants withdrew from the treatment because of self-
reported side effects induced by NTX (2) or because of relapse (6). The overall dropout
was 32%.
In general, most participants tolerated NTX well, but 73% found the taste of the NTX
fluid unpleasant. The 50-mg doses NTX-treated participants (13) experienced more side
effects compared to the 25-mg doses NTX-treated participants. Reported side effects were
headache, dizziness, nausea, insomnia, sleepiness, and decrease of taste. Due to this, in the
50-mg NTX condition, five participants halved the dose to 25 mg. Three participants refused
to continue with NTX because of side effects. As previously reported, two participants
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Table 4
Scores on the SCL-90 at baseline and at the end of treatment
Baseline End of treatment
SUBSCALE SCL-90 (n = 14) (n = 14) p
Anxiety 12.79 (2.29) 11.93 (1.94) NS
Agoraphobia 8.00 (1.24) 7.57 (0.94) NS
Depression 21.43 (3.90) 20.07 (3.97) <.05
Som. complaints 16.43 (2.88) 15.50 (3.08) NS
Insufficiency 12.43 (2.71) 12.07 (2.73) NS
Sensitivity 22.79 (3.87) 22.29 (5.31) NS
Hostility 6.86 (.77) 6.79 (.80) NS
Insomnia 5.21 (1.67) 4.79 (1.81) NS
Psychotism 11.07 (1.86) 10.50 (1.51) NS
Psneur 117.00 (15.61) 111.50 (16.68) NS
Note: Displayed are numbers, mean scores, standard deviations, and significant-
levels (p < 0. 05) for sub scales and total scores (Psneur) of the SCL-90.
allocated to the 50-mg condition dropped out. This left only three participants to be compli-
ant in the 50-mg condition. In contrast, only one participant allocated to the 25-mg condition
decreased the daily dose NTX to 12.5 mg. An intention to treat analysis showed no signif-
icant difference between the NTX conditions. As a result, the two NTX conditions were
collapsed.
Treatment Attendance, Satisfaction and Evaluation
CRA participants did attend a mean number of 4.5 (SD = 1.2, range = 1–5) sessions.
Participants who received CRA were, in general, satisfied with the contents and method of
the CRA therapy (Mean = 7.3, SD = 0.90, range = 6.0–9.3). The satisfaction about the
received treatment in general, measured with the CSQ-8, was high (Mean = 25.8, SD =
4.0, range = 22–32).
Abstinence and Treatment
The correlation between self-report daily smoked cigarettes and the cotinine values (T0,
T1, T4, T9, T10) is 0.675 (p < 0.01), with respect to three categories of smokers (Table 3).
When the categories were collapsed into the dichotomous measure abstinent or smoking,
the correlation between the cotinine values and self-report is perfect (1.00, p < 0.01). At
3 months after the end of treatment (T10) the abstinence rate in the CRA group was higher
than in the non-therapy group (46% vs. 25%), but this did not differ significantly. At the
11/2-year follow-up (T11), participants were asked by telephone: ”Do you smoke?” One
hundred percent of the participants gave a self-report. The smoking abstinence rate for the
non-CRA condition was 17%. In the CRA therapy group the abstinence rate was 31% (NS).
The overall abstinence rate after 11/2 years was 24%. Sixty-seven percent of the participants
who were abstinent after 3 months remained abstinent thereafter.
Craving Outcomes
Craving significantly declined each weekly measurement with a regression coefficient of
0.28 points (SD = 0.24) on the VAS scale of 0–10 (t = 5.3, df = 20, p < 0.001; Fig. 2).
There is a significant interaction (F = 2.47, df = 6.5, and 104.2, p = 0.025) between the
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Figure 2. Box plot representing the craving (VAS) distribution (T0–T10). Outliers and extremes are
suppressed. Black line in the box represents the median value. Horizontal lines under and above the
box (whiskers) indicate the range of values (excluding outliers and extremes). Length of box indicates
the interquartile range (IQR), which covers the range between the 25th and 75th quartile. The IQR is
an estimate of the spread of the data.
sequential time points and baseline craving. The interaction effect indicates that the higher
the participants’ baseline craving, the stronger the decrease in craving. The correlation
between baseline level of craving and the slope of craving is −0.53 (p = 0.014). The VAS
measures pertaining to the taste of the cigarette, if the participant had smoked, showed
neither interaction effects nor a significant trend.
Discussion
This study yielded a high agreement between biochemical cotinine values and self-reported
tobacco consumption. Consequently, the abstinence rates can be considered as valid. An
effect of CRA therapy is suggested with nearly double the amount of abstinence. However,
the difference is not significant. This lack of a significant effect may be due to the small
study sample. To calculate the number of participants we would have needed to find a
statistically significant effect. We merged the data (proportions of abstinence at 3 months;
25% vs. 46%, power .8, and alpha .05) in an Arcsin formula (Lemeshow et al., 1990;
Lwanga and Lemeshow, 1991). This resulted in 63 participants in each group (one-sided).
Another concern is the relatively large amount of time consumed to collect data, provide
information, and give instructions by a researcher. This considerable amount of attention
may have diluted the CRA effect.
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Due to side effects, a comparison between the 25-mg and the 50-mg NTX doses was
not meaningful. Noncompliance with regard to doses contaminated the conditions, which
impaired the randomization procedure. More than 50% of the participants in the 50-mg
NTX condition reduced the doses to 25 mg or to none. Participants were generally satisfied
with the treatment and NTX, but still suffered side effects, even with 25-mg doses. Side
effects after NTX induction have also previously been reported (Sutherland et al., 1995;
Brauer et al., 1999). However, the severity of the side effect has not caused such a high
noncompliance in a 50-mg condition as in previous studies. Seventy-three percent of the
participants rated the taste of the NTX oral solution (10-ml) as unpleasant, which might
have been caused by relative large doses of concomitant additives such as saccharine (1 mg)
and sorbitol (70%).
There was a significant decline in craving and a significant interaction between baseline
craving and decline in craving. Methodological limitations preclude us drawing firm con-
clusions regarding the effect of NTX on craving, but the findings do suggest that additional
research on NTX related to craving is warranted, as analogue results previously have been
reported (King and Meyer, 2000).
The protocol-driven cognitive behavioral treatment program based on CRA is rather
extensive in comparison to many regular smoking cessation programs (especially self-
help), which could compromise participants’ satisfaction. Results indicate, however, that
participants were satisfied with the CRA program and found the frequency and the duration
of the treatment appropriate.
With regard to methodological limitations, non-blinding of the conditions, small sam-
ple size, and the necessity for collapsing the two NTX dose conditions, we were limited
to ascertain an effect between 25-mg and 50-mg NTX condition. Further double blind,
(placebo) controlled research in a larger population is needed to establish the effects of a
low dose of NTX and/or NRT on smoking behavior. We recommend in further research the
administration of NTX in pill form. CRA constitutes an innovative approach in smoking
cessation treatment. The results in this study support the call for further research.
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RESUME
L’approche du renforcement communautaire (Community Reinforcement Approach - CRA)
est une solution promettante pour le traitement des toxicomanes. L’antagoniste opiace´
56 Roozen et al.
Naltrexone (NTX), utilise´ en combinaison avec une the´rapie de remplacement de la nicotine
(Nicotine Replacement Therapy–NRT) pourrait eˆtre effectif pour bloquer les stimuli des
fumeurs en abstinence. Des effets n’ont pas e´te´s enregistre´s pour des doses infe´rieures a`
50 mg/j. L’objectif de la pre´sente e´tude e´tait de comprendre les effets de la combinaison NTX
(25/50-mg/j.), NRT et CRA en termes de ‘craving’ et d’abstinence. L’e´tude a e´te´ conduite en
l’an 2000/2001, a` Amsterdam, aux Pays-Bas. De manie`re ale´atoire, les 25 participants ont
rec¸u un traitement de 8 semaines selon la me´thode ‘2 × 2 between subjects’. Du a` des effets
secondaires, seulement 3 participants ont comple´te´ le traitement suivant la me´thode pre´vue.
Le ‘craving’ diminua de manie`re signifiante entre chaque controˆle et il y avait une relation
signifiante entre la diminution du ‘craving’ et le niveau de ‘craving’ mesure´ initialement.
Trois mois apre`s la fin de l’e´tude, le niveau d’abstinence dans le groupe CRA e´tait plus haut
que dans le groupe qui n’avait pas rec¸u ce traitement (46% vs. 25%; NS).
RESUMEN
La Aproximacio´n de Reforzamiento Comunitario (Community Reinforcement Approach-
CRA) compone una de las opciones ma´s prometedoras dentro del tratamiento de las
drogodependencias. Un antagonista opia´ceo como la Naltrexona (NTX) usado en com-
binacio´n con una terapia sustitutoria de nicotina (Nicotine Replacement Therapy-NRT)
puede ser efectivo para bloquear los efectos de los el deseo de fumar que padecen los
fumadores en el periodo de abstinencia. Los efectos de dosis de NTX por debajo de 50
mg/dd no han sido au´n investigados. El objetivo de este estudio es investigar si la com-
binacio´n de NTX (25/50-mg dd.), con una terapia sustitutoria de nicotina y con la CRA
es efectiva operacionalizada en te´rminos de “craving” y abstinencia. El estudio se llevo a
cabo en los an˜os 2000/2001 en Amsterdam, Holanda. Los 25 participantes recibieron un
tratamiento de 8 semanas y fueron alocados de forma random dentro de un disen˜o 2X2
con un factor intragrupo (random open label within-subjects design). Debido a los efectos
secundarios de las dosis de 50 mg de NTX so´lo 3 participates terminaron el tratamiento
en esta condicio´n. El “craving” descendio´ significativamente entre cada medida y hubo
una interaccio´n significativa entre el descenso del “craving” y el “craving” registrado en
la primera medida. El nivel de abstinencia tres meses despue´s del final del tratamiento fue
ma´s alto en el grupo que recibio´ la CRA que en el grupo que no recibio´ dicha intervencio´n
(46% vs. 25%, NS).
SAMENVATTING
Middels een pilotstudie in Amsterdam in 2000/2001 werd de combinatie Community Re-
inforcement Approach (CRA), naltrexon (NTX) en een nicotinesubstitutie behandeling
onderzocht (NRT). De farmacotherapie werd voornamelijk ingezet om “craving” te vermin-
deren en CRA werd toegepast als terugvalpreventie om het rookgedrag van de deelnemer
te veranderen.. NTX werd in de vorm van 2 verschillende doseringen aangeboden om de
invloed te onderzoeken op “craving.” NRT werden voor de duur van e´e´n week aangebo-
den en langzaam afgebouwd. Dit om onthoudings klachten te verminderen. In een geran-
domiseerd open label (2 × 2) design werden 25 spontaneous pneumothorax (SP) patie¨nten
behandeld. De 4 groepen waren CRA vs. non-psychosociale therapie. NTX 25 mg/dd vs.
NTX 50mg/dd. Door bijwerkingen van NTX waren slechts 3 deelnemers van de 50 mg
conditie therapietrouw. Daarom werden de 25 mg en 50 mg conditie geaggregeerd. De
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“craving” verminderde voor de gehele groep statistisch significant over de tijd. Bovendien
is er een interactie effect tussen baseline “craving” en vermindering van “craving” gemeten
over de verschilende tijdsintervallen. Alhoewel niet statistisch significant, een groter aantal
patie¨nten in de CRA conditie waren abstinent in vergelijking tot de non-therapie groep 3
maanden na het eind van de behandeling (46% vs. 25%).
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Glossary
Community Reinforcement Approach (CRA). A cognitive behavioral oriented treatment
package to rearrange a substance abusing lifestyle.
Craving. Considered as a compulsory desire to use substances.
Naltrexone (NTX). An opioid antagonist, blocks intrinsic properties of psychoactive sub-
stances that act op the µ, κ , and δ opioid receptor sites.
Nicotine Replacement Therapy (NRT). A therapy wherein Transdermal Nicotine Patches
(TNP) are used as a substitute, because nicotine is readily absorbed through the skin.
The patches are offered in three different doses 21 mg (30 cm2), 14 mg (20 cm2), and
7 mg (10 cm2).
Spontaneous Pneumothorax (SP). A partial or complete collapse of the lung (see Smit,
1999).
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